Author | Kojic, Erna Milunka | |
Author | Kang, Minhee | |
Author | Cespedes, Michelle S. | |
Author | Umbleja, Triin | |
Author | Godfrey, Catherine | |
Author | Allen, Reena T. | |
Author | Firnhaber, Cynthia | |
Author | Grinsztejn, Beatriz | |
Author | Palefsky, Joel M. | |
Author | Cyriaque, Jennifer Y. Webster | |
Author | Saah, Alfred | |
Author | Aberg, Judith A. | |
Author | Cu-Uvin, Susan | |
Access date | 2015-06-30T16:05:15Z | |
Available date | 2015-06-30T16:05:15Z | |
Document date | 2014 | |
Citation | KOJIC, Erna Milunka et al. Immunogenicity and safety of the quadrivalent human papillomavirus vaccine in HIV-1– infected women. Clinical Infectious Diseases, v.59, n.1, p.127-135, 2014. | pt_BR |
ISSN | 1058-4838 | |
URI | https://www.arca.fiocruz.br/handle/icict/11016 | |
Language | eng | pt_BR |
Publisher | Oxford University Press | pt_BR |
Rights | restricted access | pt_BR |
Title | Immunogenicity and safety of the quadrivalent human papillomavirus vaccine in HIV-1– infected women | pt_BR |
Type | Article | pt_BR |
DOI | 10.1093/cid/ciu238 | |
Abstract | Background. Women infected with human immunodeficiency virus (HIV) are disproportionately affected by human papillomavirus (HPV)–related anogenital disease, particularly with increased immunosuppression. AIDS Clinical Trials Group protocol A5240 was a trial of 319 HIV-infected women in the United States, Brazil, and South Africa to determine immunogenicity and safety of the quadrivalent HPV vaccine in 3 strata based on screening CD4 count: >350 (stratum A), 201–350 (stratum B), and ≤200 cells/µL (stratum C).
Methods. Safety and serostatus of HPV types 6, 11, 16, and 18 were examined. HPV serological testing was performed using competitive Luminex immunoassay (HPV-4 cLIA). HPV type-specific seroconversion analysis was done for participants who were seronegative for the given type at baseline.
Results. Median age of patients was 36 years; 11% were white, 56% black, and 31% Hispanic. Median CD4 count was 310 cells/µL, and 40% had undetectable HIV-1 load. No safety issues were identified. Seroconversion proportions among women at week 28 for HPV types 6, 11,16, and 18 were 96%, 98%, 99%, and 91%, respectively, for stratum A; 100%, 98%, 98%, and 85%, respectively, for stratum B, and 84%, 92%, 93%, and 75%, respectively, for stratum C.
Conclusions. The quadrivalent HPV vaccine targeted at types 6, 11, 16, and 18 was safe and immunogenic in HIV-infected women aged 13–45 years. Women with HIV RNA load >10 000 copies/mL and/or CD4 count <200 cells/µL had lower rates of seroconversion rates. | pt_BR |
Affilliation | Brown University. Department of Infectious Disease. Providence, RI, United States of America | pt_BR |
Affilliation | Harvard School of Public Health. Center for Biostatistics in AIDS Research. Boston, MA, United States of America | pt_BR |
Affilliation | Icahn School of Medicine at Mount Sinai. Division of Infectious Diseases. New York City, NY, United Sates of America | pt_BR |
Affilliation | Harvard School of Public Health. Center for Biostatistics in AIDS Research. Boston, MA, United States of America | pt_BR |
Affilliation | National Institute of Allergy and Infectious Diseases. National Institutes of Health. HIV Research Branch. Therapeutics Research Program. Division of AIDS. Bethesda, MD, United States of America | pt_BR |
Affilliation | AIDS Clinical Trials Group Network Coordinating Center. Silver Spring, MD, United States of America | pt_BR |
Affilliation | University of the Witwatersrand. Department of Internal Medicine. Faculty of Health Sciences. Clinical HIV Research Unit. Johannesburg, South Africa | pt_BR |
Affilliation | Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Rio de Janeiro, RJ, Brasil | pt_BR |
Affilliation | University of California. Department of Medicine. San Francisco, CA, United States of America | pt_BR |
Affilliation | University of North Carolina. Oral HIV/AIDS Research Alliance. Virology, Microbiology and Immunology, Dental Ecology. Chapel Hill, NC, United States of America | pt_BR |
Affilliation | Merck Research Labs. North Wales, PA, United States of America | pt_BR |
Affilliation | Icahn School of Medicine at Mount Sinai. Division of Infectious Diseases. New York City, NY, United Sates of America | pt_BR |
Affilliation | Brown University. Department of Infectious Disease. Providence, RI, United States of America | pt_BR |
Subject | Papillomavirus Vaccines | pt_BR |
Subject | HIV | pt_BR |
Subject | Immunosuppression | pt_BR |
Subject | Statistical Analysis | pt_BR |
DeCS | Vacinas contra Papillomavirus | pt_BR |
DeCS | HIV | pt_BR |
DeCS | Imunossupressão | pt_BR |
DeCS | Análise Estatística | pt_BR |
e-ISSN | 1537-6591 | |